Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma (REPLACE)
A Phase II Study of Neoadjuvant Chemotherapy + IMRT Combined With Cetuximab in Advanced T Stage of Nasopharyngeal Carcinoma
Sponsor: Affiliated Cancer Hospital of Shantou University Medical College
This PHASE2 trial investigates Nasopharyngeal Carcinoma and is currently completed. Affiliated Cancer Hospital of Shantou University Medical College leads this study, which shows 8 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Aug 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Sep 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Affiliated Cancer Hospital of Shantou University Medical College
- First People's Hospital of Foshan
- Hubei Cancer Hospital
- Hunan Cancer Hospital
- Jiangxi Provincial Cancer Hospital
- Shenzhen People's Hospital
- Sun Yat-sen University
- The First Affiliate Hospital of Guangxi Medical College
- Tongji University
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Wenzhou Medical University
- Wuhan University
- Xijing Hospital
- Zhejiang Cancer Hospital
For direct contact, visit the study record on ClinicalTrials.gov .